Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2008, Pages 458-467

  Bourliere, M ^b   Penaranda, G ^c   Ouzan, D ^d   Renou, C ^e   Botta Fridlund, D ^f   Tran, A ^g   Rosenthal, E ^g   Wartelle Bladou, C ^h   Delasalle, P ⁱ   Oules, V ^b   Portal, I ^f   Castellani, P ^b   Lecomte, L ^b   Rosenthal Allieri, M A ^g   Halfon, P ^a  

^a Laboratoire Alphabio   (France)

^b HÔPITAL SAINT JOSEPH   (France)

^c CDL Pharma   (France)

^d INSTITUT ARNAULT TZANCK   (France)

^e Centre Hospitalier Général de Hyères   (France)

^f HÔPITAL DE LA CONCEPTION   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h CENTRE HOSPITALIER DU PAYS D AIX   (France)

ⁱ Cabinet d'Hépato Gastroentérologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELETS RATIO INDEX; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FIBROTEST; HEPASCORE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 47749118790     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03742.x     Document Type: Article

References (34)

1. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001 344 : 495 500.
2. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 32 : 477 81.
3. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 8.
4. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 75.
5. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 26.
6. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 (4 Pt 1 986 92.
7. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005 51 : 1867 73.
8. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005 42 : 1373 81.
9. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006 44 : 686 93.
10. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006 101 : 547 55.
11. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 50.
12. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005 42 : 838 45.
13. Halfon P. Fibrotest limits in hepatitis C management. Gastroenterol Clin Biol 2006 30 : 117 20.
14. Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem 2005 38 : 473 8.
15. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006 13 : 659 70.
16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24 : 289 93.
17. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 : 839 43.
18. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007 46 : 395 402.
19. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003 39 : 239 44.
20. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 57.
21. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007 46 : 775 82.
22. Poynard T, Halfon P, Castera L, et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007 25 : 733 9.
23. Netto GJ, Watkins DL, Williams JW, et al. Interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the 'hepatitis C 3' multi-institutional trial experience. Arch Pathol Lab Med 2006 130 : 1157 62.
24. Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999 19 : 183 7.
25. Gronbaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J Viral Hepat 2002 9 : 443 9.
26. Schiano TD, Azeem S, Bodian CA, et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005 3 : 930 5.
27. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007 102 : 2589 600.
28. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005 41 : 257 64.
29. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 50 : 1344 55.
30. Poynard T, Halfon P, Castera L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007 53 : 1615 22.
31. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007 31 : 504 9.
32. Boursier J, Dib N, Oberti F, Cales P. Characteristics and interpretation of blood tests for liver fibrosis. Gastroenterol Clin Biol 2007 31 : 511 23.
33. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004 42 : 323 33.
34. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005 4 : 10.